Publication date: February 24, 2025
Although the SGH Business Game may be associated with the broadly understood field of management, it is worth emphasizing that participation in this competition is not limited only to people associated with economic sciences. Law students, participating in the competition, get to know issues in the field of management, negotiations or business law.
More
Publication date: February 20, 2025
Today (February 20) we had participated in the webinar organised by the Life Science Cluster, devoted to the impact of the AI Act regulation on the life science sector – its importance and consequences for entrepreneurs.
More
Publication date: February 19, 2025
Introduction: The ambivalence of the issue and the regulatory context
The issue of informing the patient about the drug is of key importance in the treatment process, because the proper provision of information can affect the effectiveness of the therapy, patient safety and minimizing the risk of adverse effects. From a regulatory perspective, the rules regarding drug leaflets are precisely defined in both national and EU legal acts, but in practice we encounter differences in the formulation of this information by manufacturers, even in relation to products intended for the treatment of the same condition.
A comparative analysis based on the example of the comparative leaflets of two sample drugs, Maxitrol and Floxal – two preparations used in the treatment of blepharitis, although differing in composition and mechanism of action – reveals a certain editorial freedom of the manufacturers in shaping the content of the leaflets.
On the one hand, the law regulates in detail the requirements for the content of leaflets, on the other hand, there is flexibility in their formulation, especially in stylistic and organizational matters. The aim of this report is to provide an in-depth analysis of the legal provisions regulating this issue, as well as to present a comparison of two leaflets, taking into account both their substantive content and form.
Report objectives:
- Understand the laws that govern prescription drug information leaflets.
- Analysis of the details of the presentation of active substances, dosage, contraindications, etc.
- An assessment of the extent to which the drug manufacturer has freedom to edit such information and what the legal consequences of these choices are.
Legal Basis for Prescription Drug Disclosure Obligations
More
Publication date: February 19, 2025
Employers often address the question whether it is legal and possible to end employment relationship with the employee and enter into civil law relationship or B2B contract.
This article presents possibilities, risks and limitations of replacing employment contract with civil law contract.
At the outset, it is worth paying attention to the legal provision of the Polish Labour Code, namely Article 22 § 1, which states that:
“§ 1. By entering into an employment relationship, the employee undertakes to perform work of a specified type for the employer and under his supervision and at the place and time designated by the employer, and the employer undertakes to employ the employee for remuneration.”
More
Publication date: February 18, 2025
The classically understood merger and acquisition in Polish legal doctrine concern issues closely related to private economic law. In the classical understanding of these concepts, a merger is a combination of two or more companies as a result of which they create one entity. A takeover also occurs in the Polish legal system, but this institution differs from a merger. As a result of a takeover, no new legal entity is created, and the acquiring company gains control over the assets and activities of the acquired company. Both institutions are regulated by the Commercial Companies Code, where both of these institutions are regulated in Title IV of the aforementioned code. The M&A can also be understood more broadly, as the purchase of technology or organised part of the enterprise.
More
